Alexandre P Zavascki

List of Publications by Year
in descending order

134 papers	5,514 citations	109321 35 h-index	91884 69 g-index
134 all docs	134 docs citations	134 times ranked	5810 citing authors

#	Article	IF	Citations
1	Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. Journal of Antimicrobial Chemotherapy, 2007, 60, 1206-1215.	3.0	695
2	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiâ€infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy, 2019, 39, 10-39.	2.6	545
3	Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens. Clinical Infectious Diseases, 2013, 57, 524-531.	5.8	351
4	Clinical Characteristics of Covid-19 in China. New England Journal of Medicine, 2020, 382, 1859-1862.	27.0	275
5	Multidrug-resistantPseudomonas aeruginosaandAcinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Review of Anti-Infective Therapy, 2010, 8, 71-93.	4.4	256
6	Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients. Clinical Infectious Diseases, 2008, 47, 1298-1304.	5.8	208
7	Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	152
8	Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. International Journal of Antimicrobial Agents, 2014, 43, 349-352.	2.5	120
9	Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Review of Anti-Infective Therapy, 2013, 11, 1333-1353.	4.4	112
10	Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. Antimicrobial Agents and Chemotherapy, 2016, 60, 2443-2449.	3.2	104
11	The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. Journal of Antimicrobial Chemotherapy, 2010, 65, 2231-2237.	3.0	101
12	Reduction in Inddence of Nosocomial Methicillin-Resistant Staphylococcus aureus (MRSA) Infection in an Intensive Care Unit: Role of Treatment With Mupirocin Ointment and Chlorhexidine Baths for Nasal Carriers of MRSA. Infection Control and Hospital Epidemiology, 2006, 27, 185-187.	1.8	100
13	The influence of metallo-Â-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. Journal of Antimicrobial Chemotherapy, 2006, 58, 387-392.	3.0	99
14	Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. Journal of Antimicrobial Chemotherapy, 2015, 70, 1552-1557.	3.0	98
15	Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-Î²-lactamase in a teaching hospital in southern Brazil. Journal of Antimicrobial Chemotherapy, 2005, 56, 1148-1151.	3.0	78
16	Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity. Antibiotics, 2019, 8, 24.	3.7	76
17	Characterization of Tn 3000 , a Transposon Responsible for bla _{NDM-1} Dissemination among Enterobacteriaceae in Brazil, Nepal, Morocco, and India. Antimicrobial Agents and Chemotherapy, 2015, 59, 7387-7395.	3.2	70
18	Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two caseâ€“control studies in hospitalized patients. Journal of Hospital Infection, 2005, 59, 96-101.	2.9	68

#	Article	IF	Citations
19	Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. Journal of Antimicrobial Chemotherapy, 2013, 68, 674-677.	3.0	63
20	Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections. Antimicrobial Agents and Chemotherapy, 2015, 59, 6575-6580.	3.2	58
21	Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. Journal of Antimicrobial Chemotherapy, 2011, 66, 175-179.	3.0	55
22	Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal, 2022, 59, 2101471.	6.7	55
23	Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study. Critical Care, 2006, 10, R114.	5.8	52
24	Fungal Thyroiditis: An Overview. Mycopathologia, 2006, 161, 129-139.	3.1	50
25	The changing epidemiology of Acinetobacter spp. producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report. Diagnostic Microbiology and Infectious Disease, 2015, 83, 382-385.	1.8	50
26	Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Brazilian Journal of Infectious Diseases, 2012, 16, 416-419.	0.6	49
27	Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa. Journal of Medical Microbiology, 2013, 62, 1184-1189.	1.8	48
28	The need for reappraisal of AIDS score weight of Charlson comorbidity index. Journal of Clinical Epidemiology, 2007, 60, 867-868.	5.0	47
29	Dissemination of Pseudomonas aeruginosa Producing SPM-1-like and IMP-1-like Metallo-Î²-lactamases in Hospitals from Southern Brazil. Infection, 2007, 35, 457-460.	4.7	47
30	Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiology, 2012, 12, 196.	3.3	46
31	Polymyxin B Resistance in Carbapenem-ResistantKlebsiella pneumoniae, SÃ£o Paulo, Brazil. Emerging Infectious Diseases, 2016, 22, 1849-1851.	4.3	45
32	Emergence of NDM-1-producing Enterobacteriaceae in Porto Alegre, Brazil. International Journal of Infectious Diseases, 2014, 25, 79-81.	3.3	44
33	Aminoglycosides against carbapenem-resistantEnterobacteriaceaein the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Review of Anti-Infective Therapy, 2017, 15, 519-526.	4.4	44
34	Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-Â-lactamase in two tertiary-care teaching hospitals. Journal of Antimicrobial Chemotherapy, 2006, 58, 882-885.	3.0	40
35	Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. Journal of Antimicrobial Chemotherapy, 2008, 62, 1009-1014.	3.0	38
36	Acquisition of the mcr-1 gene by a high-risk clone of KPC-2-producing Klebsiella pneumoniae ST437/CC258, Brazil. Diagnostic Microbiology and Infectious Disease, 2018, 90, 132-133.	1.8	37

#	Article	IF	Citations
37	Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	36
38	A Cohort Study of the Impact of Carbapenem-Resistant Enterobacteriaceae Infections on Mortality of Patients Presenting with Sepsis. MSphere, 2019, 4, .	2.9	35
39	Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2019, 53, 152-157.	2.5	35
40	Letter to the editor: Escherichia coli harbouring mcr-1 gene isolated from poultry not exposed to polymyxins in Brazil. Eurosurveillance, 2016, 21, .	7.0	34
41	Detection of OXA-370, an OXA-48-Related Class D Î²-Lactamase, in Enterobacter hormaechei from Brazil. Antimicrobial Agents and Chemotherapy, 2014, 58, 3566-3567.	3.2	33
42	Paecilomyces variotiias an Emergent Pathogenic Agent of Pneumonia. Case Reports in Infectious Diseases, 2013, 2013, 1-3.	0.5	32
43	Emergence of NDM-1-producing Acinetobacter pittii in Brazil. International Journal of Antimicrobial Agents, 2015, 45, 444-445.	2.5	31
44	Risk factors for and mortality of extended-spectrum-Î²-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2009, 51, 211-216.	1.1	30
45	Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates. Annals of Clinical Microbiology and Antimicrobials, 2013, 12, 15.	3.8	30
46	Outbreak of Carbapenem-Resistant Providencia stuartii in an Intensive Care Unit. Infection Control and Hospital Epidemiology, 2012, 33, 627-630.	1.8	28
47	Co-occurrence of mcr-1 and blaKPC-2 in a clinical isolate of Escherichia coli in Brazil. Journal of Antimicrobial Chemotherapy, 2017, 72, 2404-2406.	3.0	26
48	Clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus carrying SCCmecIV in a university hospital in Porto Alegre, Brazil. Diagnostic Microbiology and Infectious Disease, 2009, 65, 457-461.	1.8	25
49	Clinical Use of Polymyxin B. Advances in Experimental Medicine and Biology, 2019, 1145, 197-218.	1.6	25
50	Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Infection, 2013, 41, 321-328.	4.7	24
51	Comparable Efficacy and Better Safety of Double Î²-Lactam Combination Therapy versus Î²â€˜Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
52	Activity of Antimicrobial Combinations against KPC-2-Producing Klebsiella pneumoniae in a Rat Model and Time-Kill Assay. Antimicrobial Agents and Chemotherapy, 2015, 59, 4301-4304.	3.2	23
53	Corynebacterium striatum infecting a malignant cutaneous lesion: the emergence of an opportunistic pathogen. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2009, 51, 115-116.	1.1	21
54	Molecular characterization of Klebsiella pneumoniae carbapenemase-producing isolates in southern Brazil. Journal of Medical Microbiology, 2013, 62, 1721-1727.	1.8	21

#	Article	IF	Citations
55	Detection of bla _{GES-5} in Carbapenem-Resistant Kluyvera intermedia Isolates Recovered from the Hospital Environment. Antimicrobial Agents and Chemotherapy, 2014, 58, 622-623.	3.2	21
56	Head and Neck Hyperpigmentation Probably Associated With Polymyxin B Therapy. Annals of Pharmacotherapy, 2015, 49, 1171-1172.	1.9	20
57	KPC-2-producing Enterobacter cloacae in two cities from Southern Brazil. International Journal of Antimicrobial Agents, 2009, 34, 286-288.	2.5	19
58	Vancomycin and creatinine determination in dried blood spots: Analytical validation and clinical assessment. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1137, 121897.	2.3	19
59	Pneumocystis jiroveci thyroiditis: report of 15 cases in the literature. Mycoses, 2007, 50, 443-446.	4.0	18
60	Vancomycin MIC for Methicillin-Resistant Coagulase-Negative Staphylococcus Isolates: Evaluation of the Broth Microdilution and Etest Methods. Journal of Clinical Microbiology, 2010, 48, 4652-4654.	3.9	18
61	Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B. International Journal of Antimicrobial Agents, 2016, 47, 146-150.	2.5	18
62	KPC-2-producing Klebsiella pneumoniae in Brazil: A widespread threat in waiting?. International Journal of Infectious Diseases, 2010, 14, e539-e540.	3.3	17
63	Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1681-1687.	3.0	17
64	Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five Î²-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae. MBio, 2020, 11, .	4.1	17
65	Cystic Fibrosis Patient with Burkholderia pseudomallei Infection Acquired in Brazil. Journal of Clinical Microbiology, 2007, 45, 4077-4080.	3.9	16
66	Intravenous colistimethate for multidrug-resistant Gram-negative bacteria. Lancet Infectious Diseases, The, 2008, 8, 403-405.	9.1	16
67	In Vitro Activity of Polymyxin B plus Imipenem, Meropenem, or Tigecycline against KPC-2-Producing Enterobacteriaceae with High MICs for These Antimicrobials. Antimicrobial Agents and Chemotherapy, 2015, 59, 3596-3597.	3.2	16
68	Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation. International Journal of Antimicrobial Agents, 2016, 48, 579-580.	2.5	16
69	Detection of blaKPC-2 in a carbapenem-resistant Kluyvera georgiana. Journal of Antimicrobial Chemotherapy, 2012, 67, 2776-2777.	3.0	15
70	Four Decades of Î²-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. Clinical Pharmacokinetics, 2019, 58, 143-156.	3.5	15
71	Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1525-1537.	2.5	15
72	Risk factors for 30-day mortality in patients with carbapenem-resistantAcinetobacter baumanniiduring an outbreak in an intensive care unit. Epidemiology and Infection, 2011, 139, 411-418.	2.1	13

#	Article	IF	Citations
73	High Endemic Rates of OXA-23-Producing Carbapenem-Resistant Acinetobacter baumannii Isolates Caused by the Persistence of Major Clones in Hospitals in a Brazilian City 5 Years After an Outbreak. Infection Control and Hospital Epidemiology, 2015, 36, 860-862.	1.8	13
74	Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing Klebsiella pneumoniae causing bloodstream infection in a neutropenic patient during polymyxin B therapy. Diagnostic Microbiology and Infectious Disease, 2018, 90, 134-138.	1.8	13
75	Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2009, 51, 111-113.	1.1	13
76	First Case Report of Neisseria lactamica Causing Cavitary Lung Disease in an Adult Organ Transplant Recipient. Journal of Clinical Microbiology, 2006, 44, 2666-2668.	3.9	12
77	Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma--authors' response. Journal of Antimicrobial Chemotherapy, 2009, 63, 628-629.	3.0	12
78	Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside. Expert Review of Anti-Infective Therapy, 2014, 12, 531-533.	4.4	12
79	Carbapenem-resistant GES-5-producing Klebsiella pneumoniae in Southern Brazil. Brazilian Journal of Infectious Diseases, 2014, 18, 231-232.	0.6	12
80	Detection of Enterobacterales resistant to polymyxins using Rapid Polymyxins NP test. Brazilian Journal of Microbiology, 2019, 50, 425-428.	2.0	12
81	Intracranial Tuberculomas in an Immunocompetent Patient Mimicking Brain Metastasis of Unknown Origin. Infection, 2006, 34, 181-182.	4.7	11
82	Nosocomial bloodstream infections due to metallo-Â-lactamase-producing Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2008, 61, 1183-1185.	3.0	11
83	Lactobacillus rhamnosus bacteremia in a kidney transplant recipient. Transplant Infectious Disease, 2015, 17, 610-612.	1.7	11
84	Ocurrence of blaSPM-1 and blaIMP-1 genes of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa from three universitary hospitals in the city of Porto Alegre, Brazil. Brazilian Journal of Microbiology, 2007, 38, 108-109.	2.0	11
85	Performance of Quantification of Modified Hodge Test: An Evaluation withKlebsiella pneumoniaeCarbapenemase-Producing Enterobacteriaceae Isolates. BioMed Research International, 2014, 2014, 1-6.	1.9	10
86	Assessing Risk Factors for Acquiring Antimicrobial-Resistant Pathogens: A Time for a Comparative Approach. Clinical Infectious Diseases, 2004, 39, 871-872.	5.8	9
87	High prevalence of metallo-Î²-lactamase-mediated resistance challenging antimicrobial therapy against Pseudomonas aeruginosa in a Brazilian teaching hospital. Epidemiology and Infection, 2007, 135, 343-345.	2.1	9
88	Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity. Brazilian Journal of Microbiology, 2021, 52, 1913-1919.	2.0	9
89	Detection of OXA-370 directly from rectal swabs and blood culture vials using an immunochromatographic assay. Journal of Microbiological Methods, 2017, 139, 92-94.	1.6	8
90	Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery. International Journal of Antimicrobial Agents, 2018, 52, 86-89.	2.5	8

#	Article	IF	Citations
91	Clinical usefulness of tomographic standards for COVID-19 pneumonia diagnosis: Experience from a Brazilian reference center. Brazilian Journal of Infectious Diseases, 2020, 24, 524-533.	0.6	8
92	High Rate of Antimicrobial Resistance in Pseudomonas aeruginosa at a Tertiary-Care Teaching Hospital in Southern Brazil. Infection Control and Hospital Epidemiology, 2004, 25, 805-808.	1.8	7
93	Stable Polymyxin B Susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite Persistent Recovery of These Organisms from Respiratory Secretions of Patients with Ventilator-Associated Pneumonia Treated with This Drug. Journal of Clinical Microbiology, 2009, 47, 3064-3065.	3.9	7
94	Heteroresistance to Carbapenems in New Delhi Metallo-Î²-Lactamase-1â€“Producing Isolates: A Challenge for Detection?. Infection Control and Hospital Epidemiology, 2014, 35, 751-752.	1.8	7
95	KPC-producing Klebsiella pneumoniae bloodstream isolates from Brazilian hospitals: What (still) remains active?. Journal of Global Antimicrobial Resistance, 2018, 15, 173-177.	2.2	7
96	Increased frequency of blaNDM in a tertiary care hospital in southern Brazil. Brazilian Journal of Microbiology, 2021, 52, 299-301.	2.0	7
97	Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2007, 30, 187-189.	2.5	6
98	High frequency of Â-lactam susceptibility in CTX-M-type extended-spectrum-Â-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations. Journal of Antimicrobial Chemotherapy, 2010, 65, 2481-2483.	3.0	6
99	Dose Adjustment of Polymyxins for Renal Insufficiency. Antimicrobial Agents and Chemotherapy, 2011, 55, 4940-4940.	3.2	6
100	In vitro activity of non-bactericidal concentrations of polymyxin B in combination with other antimicrobials against OXA-23-producing carbapenem-resistant Acinetobacter baumannii. Brazilian Journal of Infectious Diseases, 2013, 17, 502-504.	0.6	5
101	PCR to detect Mycobacterium tuberculosis in respiratory tract samples: evaluation of clinical data. Epidemiology and Infection, 2014, 142, 1517-1523.	2.1	5
102	Streptococcus pneumoniae appendicitis in an adult patient. American Journal of Emergency Medicine, 2015, 33, 990.e1-990.e3.	1.6	4
103	Current Status of Pseudomonas aeruginosa Vaccine. Current Pharmaceutical Biotechnology, 2014, 14, 951-959.	1.6	4
104	Determining Risk Factors for Infection with Influenza A (H5N1). Emerging Infectious Diseases, 2007, 13, 955-956.	4.3	3
105	Scanning electron microscopy of scutular tinea. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 325-327.	2.4	3
106	Lack of methicillin-resistant Staphylococcus aureus nasal carriage among patients at a primary-healthcare unit in Porto Alegre, Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2011, 53, 197-199.	1.1	3
107	Characterization of Transformants Obtained From NDM-1â€“Producing Enterobacteriaceae in Brazil. Infection Control and Hospital Epidemiology, 2017, 38, 634-636.	1.8	3
108	First report of IMP-1 in a clinical isolate of Escherichia coli in Latin America. Infection Control and Hospital Epidemiology, 2020, 41, 997-998.	1.8	3

#	Article	IF	Citations
109	Evaluation of Clinical Course of Gamma (P.1) Variant of Concern versus Lineages in Hospitalized Patients with COVID-19 in a Reference Center in Brazil. American Journal of Tropical Medicine and Hygiene, 2022, 107, 245-251.	1.4	3
110	Restricting the use of ampicillinâ€“sulbactam. Journal of Hospital Infection, 2004, 56, 165-166.	2.9	2
111	Treatment of extensively drug-resistant tuberculosis. Lancet, The, 2009, 373, 27.	13.7	2
112	Reply to Pai. Clinical Infectious Diseases, 2013, 57, 1786-1786.	5.8	2
113	Characteristics of Enterobacteriaceae Isolates Coharboring Distinct Carbapenemase Genes. Infection Control and Hospital Epidemiology, 2017, 38, 1123-1126.	1.8	2
114	Dissemination of blaOXA-370 is mediated by IncX plasmids and the Tn6435 transposon. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2165-2169.	2.9	2
115	Can ceftolozaneâ€“tazobactam treat nosocomial pneumonia?. Lancet Infectious Diseases, The, 2019, 19, 1266-1267.	9.1	2
116	Performance of polymyxin B Etest in a setting of high prevalence of KPC-producing Klebsiella pneumoniae. Journal of Global Antimicrobial Resistance, 2020, 22, 40-42.	2.2	2
117	Urgent need for evaluation of point-of-care tests as an RT-PCR-sparing strategy for the diagnosis of Covid-19 in symptomatic patients. Epidemiology and Infection, 2021, 149, e35.	2.1	2
118	Continuous intravenous administration of antibiotics. Lancet Infectious Diseases, The, 2006, 6, 259.	9.1	1
119	How Efficient Is Procalcitonin-Guided Antibiotic Use in Acute Respiratory Tract Infections in Primary Care?. Archives of Internal Medicine, 2009, 169, 1241.	3.8	1
120	Advances in the way of dealing with antibiotic exposure in studies assessing risk factors for drug-resistant pathogens. Diagnostic Microbiology and Infectious Disease, 2009, 64, 102.	1.8	1
121	Polymyxin B Consumption and Incidence of Gram-Negative Bacteria Intrinsically Resistant to Polymyxins. Infection Control and Hospital Epidemiology, 2012, 33, 536-537.	1.8	1
122	Septic arthritis caused by Neisseria pharyngis in an elderly patient with knee prosthesis. Rheumatology International, 2013, 33, 541-542.	3.0	1
123	Direct detection of blaOXA-23 gene from endotracheal aspirates by real time PCR. Brazilian Journal of Infectious Diseases, 2013, 17, 493-494.	0.6	1
124	Low doses of colistimethate: Don't rush in!. Clinical Infectious Diseases, 2017, 64, ciw818.	5.8	1
125	Colistin versus colistin plus meropenem for severe infections. Lancet Infectious Diseases, The, 2018, 18, 493-494.	9.1	1
126	Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis. Brazilian Journal of Infectious Diseases, 2018, 22, 51-54.	0.6	1

#	Article	IF	Citations
127	Diagnostic accuracy of a SARS-CoV-2 rapid test and optimal time for seropositivity according to the onset of symptoms. Cadernos De Saude Publica, 2022, 38, e00069921.	1.0	1
128	Treatment of multidrug-resistant Pseudomonas aeruginosa infections: more attention required to in-vitro studies. Clinical Microbiology and Infection, 2005, 11, 856-857.	6.0	0
129	Is High Minimal Inhibitory Concentration of Vancomycin a Predictor of Poor Response in MRSA Infections?. Archives of Internal Medicine, 2007, 167, 1206.	3.8	0
130	Predictors of Repeat Pregnancy Among HIV-1-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 368-369.	2.1	0
131	Caution when reconsidering empiric antimicrobial therapy for methicillin-resistant Staphylococcus aureus skin and soft-tissue infections. American Journal of Surgery, 2008, 196, 618-619.	1.8	0
132	Editor's Correspondence. Archives of Internal Medicine, 2009, 169, 809.	3.8	0
133	Reply to Kunin. Clinical Infectious Diseases, 2009, 48, 843-844.	5.8	0
134	1266. Melatonin for Renal Protection of Patients Treated with Polymyxin B: A Double Blind Randomized Clinical Trial. Open Forum Infectious Diseases, 2021, 8, S721-S721.	0.9	0